Approximately 60% of first-year U.S. senators and 40% of House of Representatives freshmen are worth at least $1 million, according to the Center for Responsive Politics. That makes them far richer than most of the Americans th…
The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren’t drugs at all, from smartphone apps and educational websites to social media platforms and…
From October 2010 to February 2011, biotech Clinical Data’s stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up — and making it likely to perhaps double again — is speculati…
Diabetes is a growing global scourge, but for Big Pharma it’s more of a lifesaver — and many drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes cou…